China Meheco Group Valuation
Is 600056 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 600056 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600056 (CN¥12.47) is trading above our estimate of fair value (CN¥6.93)
Significantly Below Fair Value: 600056 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600056?
Key metric: As 600056 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 600056's PE Ratio? | |
|---|---|
| PE Ratio | 20.7x |
| Earnings | CN¥901.08m |
| Market Cap | CN¥18.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 17x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 600056's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
301015 Qingdao Baheal Medical | 21.2x | 21.4% | CN¥14.7b |
000028 China National Accord Medicines | 11.9x | 6.2% | CN¥16.1b |
600511 China National Medicines | 12.7x | 9.1% | CN¥25.9b |
600998 Jointown Pharmaceutical Group | 13.2x | 17.1% | CN¥26.4b |
600056 China Meheco Group | 20.7x | n/a | CN¥18.4b |
Price-To-Earnings vs Peers: 600056 is expensive based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (14.8x).
Price to Earnings Ratio vs Industry
How does 600056's PE Ratio compare vs other companies in the CN Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 600056 is good value based on its Price-To-Earnings Ratio (20.7x) compared to the CN Healthcare industry average (34.3x).
Price to Earnings Ratio vs Fair Ratio
What is 600056's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600056's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥7.1b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥16.65
7D
-4.6%
1Y
-27.1%
Truking Technology
CN¥4.6b
Engages in medical equipment business in China and internationally.
300358
CN¥7.76
7D
-3.8%
1Y
-35.3%
iRay Technology
CN¥16.4b
Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.
688301
CN¥114.87
7D
-10.7%
1Y
-32.1%